|Publication number||US8048044 B2|
|Application number||US 12/189,374|
|Publication date||Nov 1, 2011|
|Filing date||Aug 11, 2008|
|Priority date||Aug 14, 2007|
|Also published as||CA2696313A1, US20090048555, WO2009023750A1|
|Publication number||12189374, 189374, US 8048044 B2, US 8048044B2, US-B2-8048044, US8048044 B2, US8048044B2|
|Inventors||Martin W. Stryker, Donald M. Engelman|
|Original Assignee||Stryker Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (73), Non-Patent Citations (5), Referenced by (7), Classifications (19), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present application claims the benefit of U.S. provisional application entitled DRUG DELIVERY SYSTEM, filed Aug. 14, 2007, Ser. No. 60/955,735, which is incorporated by reference in its entirety herein.
The present invention relates to a system for delivering drugs and, more specifically, to a drug delivery system that administers drugs through the surface tissue of a patient.
Current drug delivery systems include several delivery mechanisms, including transdermal delivery, inhalation, ingestion, injection, nasal delivery, ocular delivery, buccal delivery, and suppository delivery, such as anal or vaginal suppository delivery. While the human skin is an excellent anatomical and biochemical barrier, through-the-skin (TTS) therapy has been used for many years. Due to the impermeability of skin, however, only low molecular weight medications have been used successfully. As a result, delivery of many drugs or medications has been relegated to more conventional methods, and most commonly injections via hypodermic needles, ingestion, or insertion by way of suppositories. Needles, however, break the skin barrier and, hence, may increase the risk of infection and, further, the risk of exposure to health workers to transmission of diseases. Suppositories may not be as successful due to systemic elimination. With oral delivery, the drug may not reach its intended target with the desired concentration. Further, with more medications, such as chemotherapy, having deleterious effects on the body, targeting of a drug has taken on new significance. Accordingly, there is a need for an enhanced drug delivery system that would reduce the reliance on the use of needles, pills or suppositories for delivering medication and, further, that can better target the area to be treated.
Accordingly, the present invention provides a drug delivery system that can deliver a drug through the surface tissue of a patient, whether the tissue is alive or dead, thus eliminating the various problems associate with, for example, injection, ingestion, or suppositories, and may be used to better target the drug.
In one form of the invention, a drug delivery system is provided that can be used to deliver a drug or drugs through the patient's surface tissue, including skin or tissue below the skin, for example, at a wound bed or surgical incision, while overcoming the transcutaneous transport problem. The drug delivery system of the present invention provides a pressurized chamber, which aids in the delivery of the drugs to increase drug bioavailability. Further, drug delivery may be achieved by delivering the drug in a gas, vapor, or liquid or combinations thereof.
In another form of the invention, a drug delivery system includes a chamber, a source of a drug, a pressure source, and a controller. The chamber is configured for enclosing or covering at least a surface of a patient's body. The controller is in communication with the pressure source to selectively pressurize the chamber and, further, controls the transfer of the drug to the chamber wherein the drug is administered to the surface of the patient under pressure.
In one aspects when the surface of the patient is a skin surface, the drug delivery system may also include a skin poration device, which is used to enlarge the pores of the patient's skin at the surface of the patient to thereby increase the skin's porosity. For example, the skin poration device may comprise an electrical circuit for generating a current or for generating a voltage, which may be applied to the skin surface of the patient. Alternately, the skin poration device may generate an ultrasound wave in the chamber for applying an ultrasound wave to the skin surface of the patient, or generate radiation in the chamber for applying radiation to the skin surface of the patient. For example, the skin poration device may generate heat, electromagnetic radiation, microwave radiation, or RF radiation.
According to another form of the invention, a drug delivery system includes a chamber, a pressure source, a skin poration device, and a controller. The chamber is configured for enclosing or covering at least a skin surface of a patient's body. The controller is in communication with the pressure source to selectively pressurize the chamber wherein a drug applied to skin surface of the patient is administered to the skin surface of the patient under pressure. Further, the skin poration device generates a heat, wave, current, or voltage that is applied to the patient's skin to increase the skin's porosity.
In any of the above inventions, the controller may cycle the pressure between a first pressure and a second pressure, with the first pressure being different than the second pressure. For example, the second pressure may comprise a negative pressure.
In another aspect, each of the systems may include a drug reservoir, with the controller controlling the flow of the drug from the reservoir to the chamber. In yet a further aspect, the systems may also include a source of gas, which is in selective fluid communication with the chamber. Further, the controller may be used to control the fluid communication between the source of gas and the chamber. Optionally, the controller may combine the gas with the drug so that the drug is delivered in a vapor form to the chamber.
According to another aspect, the drug delivery systems may include a humidifier in selective fluid communication with the chamber. For example, the controller may control the fluid communication between the humidifier and the chamber. Again, the controller may combine the humid air with the drug and, further, with the drug and gas mixture.
According to yet another aspect, in any of the drug delivery systems noted above, the system may includes a nebulizer, which produces a spray or mist with the drug. The spray or mist is in fluid communication with the chamber. Again, the controller may control the flow of the spray or mist into the chamber.
In another aspect, the systems may include a thermal regulator, which regulates the temperature of the drug, gas, and/or moisture or mixture thereof flowing into the chamber.
According to yet another aspect, any of the chambers may be formed by a chamber wall that is configured for enclosing at least a portion of a patient's body, such as a patient's head, ear, leg, arm, wrist, chest, groin area, or may enclose substantially, if not, the entire body of the patient.
In a further aspect, the chamber may be configured to form a reservoir for holding a liquid, with the controller directing the flow of the drug into the liquid in the chamber and further pressurizing a portion of the chamber above the liquid, hence pressurizing the liquid.
According to yet another aspect, any of the drug delivery systems described above may be incorporated into a patient support. For example, the system may have a patient-facing opening for facing the patient that is in fluid communication with the chamber, which is provided at the patient support's surface wherein the weight of the patient seals the patient-facing opening against the patient's skin. Optionally, the patient support includes a plurality of the chambers and/or systems for treating several surfaces of the patient's body.
In another form of the invention, a method of delivering a drug to a patient includes providing a chamber, which is configured for enclosing at least a surface of a patient, exposing the patient's surface to a drug in vapor form, and pressurizing the chamber, wherein the drug is administered to the surface of the patient under pressure.
In another form of the invention, a method of delivering a drug to a patient includes providing a chamber, which is configured for enclosing at least a surface of a patient, directing the flow of a drug into the chamber, controlling the flow of the drug in to the chamber, and pressurizing the chamber, wherein the drug is administered to the surface of the patient under pressure.
In any of the above methods, the pressure may be cycled between a first pressure and a second pressure, with the first pressure being different than the second pressure. For example, the pressure may be cycled between a positive pressure and a negative pressure.
In yet another form of the invention, a method of delivering a drug to a patient includes providing a chamber, which is configured for enclosing at least a surface of a patient, applying a drug to a patient's surface, pressurizing the chamber, wherein the drug is administered to the surface of the patient under pressure, and cycling the pressure between two different pressure values.
In another aspect of the above methods, a gas may be directed into the chambers, which may be used to transport the drug, compliment the drug either by enhancing the absorption of the drug, and/or provide additional treatment.
Further, the humidity or temperature in the chambers may be controlled. For example, the humidity or temperature in the chambers may be increased. Optionally, when the drug is delivered to the chambers for application, the drug may be transformed into a spray or mist form and then directed into the chambers.
Accordingly, the present invention provides a drug delivery system that can deliver a drug or drugs through-the-surface-tissue, thus eliminating the various problems associate with, for example, injection, ingestion, or suppositories, and may be used to better target the drug by applying the drug or drugs to a localized surface of the patient.
These and other objects, advantages, purposes, and features of the invention will become more apparent from the study of the following description taken in conjunction with the drawings.
While reference is made herein to the term “drug” or “drugs”, it should be understood that this term is used broadly to include pharmaceuticals, including pain killers, such as opiates or steroids; hormones, such as androgens and estrogens, peptide hormones such as insulin, as well as performance enhancing drugs, such as steroid hormones; proteins, including morphogenetic proteins, such as bmp-2 and bmp-7; nutrients; antibiotics, such as tetracycline, penicillin, amoxicillin, erythromycin, for example; herbal medicine; vitamins; or other treatments. Further, when using the term “drug” or “drugs” it should be understood that this also includes any carriers, such as solvents or excipients, which may be added to the drug to aid in the delivery of the drug as well as enhance penetration or efficacy of the drug.
As best seen in
Chamber 12 is optimally a sealed chamber so that the chamber may be pressurized and the pressure more easily regulated. In order to seal access port 16, access port 16 includes a sealing member 16 a, such as a flexible boot or cuff or the like, to seal the space between the chamber wall and the patient's appendage when the chamber is in use. For example, in addition to providing a seal, an inflatable cuff may reduce or minimize contact with the appendage that is being inserted into the chamber. This is particularly desirable when dealing with treatment of an injured appendage or an appendage with a wound, including a surgical site.
In addition, a second port 18 may be provided to allow access into the chamber by a health worker. For example, port 18 may allow a health worker to topically apply a drug to the patient or to simply position the appendage in the chamber. As noted above, the drug may be in the form of a liquid, such as a lotion or the like, that may be topically applied to the appendage either before the appendage is placed in the chamber or after the appendage is placed in the chamber. After port 18 is used, port 18 is preferably closed, for example, by a door, a boot, or a flange or the like so that port 18 may then be fully sealed.
A black, water soluble dye was placed on non-living pig's foot skin and on non-living pig's flesh (no skin). Without pressure the dye just pooled on the surface. With pressure, significant penetration was achieved on both the skin and open flesh. For the pressure test, a portion of a pig's flesh and a portion of a pig's foot skin were placed in a humidified pressure chamber. One drop of black, water soluble food dye was applied to each of the pig's flesh and pig's foot skin in the humidified pressure chamber. The chamber was pressurized to 0.88 psi for five minutes then allowed to return to ambient pressure for one minute. This pressurization in the chamber was repeated ten time equaling a total time of pressurization of one hour. The pig's tissue and foot skin was frozen and sawed open to take the measurements and measured using a digital micrometer. For the skin, the penetration was measured to be about 0.072 inches, and for the flesh, the penetration was measured to be about 0.129 inches.
Alternately, as noted above, the drug may be delivered to chamber 12. As best seen in
The flow of the drug from reservoir 20 and through the nebulizer 24 may be controlled by a controller 26. For example, a suitable controller comprises a flow control valve, such as an electrically operated solenoid valve, which can be powered by a circuit with an on/off switch or the like or may be controlled by a control system 27. Control system 27 includes a central processor 27 a and an optional memory device 27 b. In addition, the control system may include a user input device 27 c, such as a keyboard, touch pad or touch screen, to allow a user to input operational parameters, such as the treatment time or duration, the magnitude of the pressure, and/or the treatment cycle time, into the control system or to select pre-selected programs or functions into the control system, which are stored, for example, in memory device 27 c. In this manner, system 10 may provide a controlled flow of the drug into the chamber. Furthermore, by introducing the drug in the form of a spray or mist, the drug may be delivered in a form that further facilitates absorption of the drug through the tissue of the patient.
In addition, as noted above, the drug may be combined or mixed with a gas supplied by a source of gas 28, including an inert gas, such as argon, or a therapeutic gas, such as oxygen, including hyperbaric oxygen, nitrous oxide, ozone, carbon dioxide, or an anesthetic gas, or the like, which is also in selective communication with chamber 12 through controller 26. The gas may facilitate the delivery of the drug to the patient's tissue by providing a medium to transport the drug into the chamber and, further, may provide additional therapy, including inhibiting microbial growth. For example, oxygen may inhibit most anaerobes, enhancing leukocyte and macrophage activity and possibly potentiating the effects of antibiotics. Thus, when oxygen is combined with a drug, including antibiotics or nutrients or the like, the effects of the drug may be enhanced in the presence of oxygen. In wound healing, hypoxia arises from disruption of the normal supply of oxygen by the blood. When oxygen is limited, tissues use a form of anaerobic metabolism that produces acid, and the more limited energy available in anaerobic metabolism limits cell growth and tissue repair. Providing oxygen to the tissue by exposing the injured tissue to an increased partial pressure of oxygen is a way to help get the needed oxygen to the cells, so that normal growth and repair can occur. Pressure cycling should facilitate the access of the gas to the tissue, and hence may provide improvement over static pressure. Further, when pulsed pressure, described more fully below, is combined with exposure to a drug the transdermal delivery may be enhanced.
For example, as noted above, central processor 27 a may include memory device 27 b, which may store a software program that is designed to offer pre-selected treatment regimes and which controls the amount of drug that is delivered to chamber 12, including controlling the period of time that the drug is administered and the amount of drug that is administered. Additionally, when combined with a gas or gases, the software program may control the amount of gas that is delivered with the drug to control the concentration of the drug in the resulting vapor. Optionally, each input (drug, gas, moisture, (described below), and heat (also described below)) may be regulated by providing a separate valve for each input or by providing a valve manifold with inlets for each input. Therefore, controller 26 may control the flow of a drug or drugs, gas, moisture, and heat independently.
As noted above, chamber 12 is optimally a sealed chamber, which may be pressurized to enhance the through-the-surface-tissue delivery of the drug to the patient. Referring again to
Further, the duration of the each cycle may be varied. For example, in one treatment option, the pressure may be cycled between two pressure values over the same period of time—that is the first pressure may be applied for a period of time having a duration of time T1, with a second pressure applied for a second period of time having the same length of time T1. Alternately, the first pressure may be applied for a different length of time than the second pressure. For example, the first pressure may be applied for a period of time having a duration of T1, while the second pressure may be applied for a period of time having a duration of time T2, where T2 is greater than or less than T1. This process may be repeated or may be varied further. For example, a third pressure may be applied for another period of time, which is greater or lesser than either the first two pressures and for a longer or shorter period of time than either of the first or second pressure periods, T1 or T2. While gradual transitions between the pressures may be used, an optimal pressure graph has at least approximately a step function in order to achieve the greatest pumping action at the cell level.
Further, as noted above, energy may be applied to the tissue of the patient being administered using the drug delivery system to heat the tissue to either increase the pores, noted above, or to heat the tissue to cause perspiration. For example, heat may be applied to increase the temperature of the patient's tissue, such as the patient's skin, in combination with the drug delivery step or simply in combination with the pressure, including a vacuum pressure, which may enhance the patient's elimination of toxins through perspiration.
The cycling periods may be controlled by control system 27 and, further, as noted above may be input directly by user interface device 27 c, such as a keypad, touch pad or a touch screen, which allows a healthcare giver to administer the treatment based on parameters that are provided to the healthcare worker independent of any stored parameters in the controller. It is believed that pressure cycling facilitates entry of the gas, in part by compression and expansion of the tissue.
Optionally, chamber 12 may be humidified, for example, by directing moisture into chamber 12 from a humidifier 34. Again, the humid air may be directly delivered to chamber 12 from humidifier or may be mixed with the drug and/or gasses in conduit 22 prior to entering chamber 12. With an increased level of humidity in chamber 12, the absorption of some drugs may be enhanced or may simply provide a more comfortable environment for the patient's appendage.
Similarly, a temperature controller 36 may be provided, which increases or decreases or maintains the temperature of the drugs, gasses, and/or moist air mixture that is directed to chamber 12. Again, the heating or cooling of the drugs, gasses, and/or moist air mixture may enhance the drug bioavailability and drug delivery. For example, when treating a patient's skin, the pores of the patient's skin may be enlarged through an increased temperature.
In addition, to enhance the absorption of the drug and/or gasses into the skin, chamber 12 may include a skin poration device 38—that is a device or process that enlarges the pore of the patient's skin by applying energy waves, ultrasonic waves, current or voltage to the skin directly. For example, a suitable skin poration device may include a circuit that generates an electrical current or voltage, which when applied to the patient's skin enlarges the pores. Alternately, the circuit may generate an ultrasound wave in the chamber, which is directed to the patient's skin, which also may enlarge the patient's pores. Alternately, the circuit may generate energy waves in the form of radiation, including magnetic radiation, microwave radiation, and/or radiofrequency radiation, in the chamber which is applied to the patient's skin to thereby enlarge the pores of the patient's skin. The skin poration device may be integrated into chamber 12 or may be provided in a separate housing that is in communication with chamber 12, such as illustrated in
After treatment, or optionally even during treatment, the waste and/or gas discharge from chamber 12 is exhausted from chamber 12 through an outlet port 40 and is directed through a conduit 42 through a filter 44, which filters any solids that are suspended in the gas discharge. Thereafter, the filtered discharge is passed through a precipitator 46, which precipitates any suspended liquids in the discharge. The balance of the discharge is then directed to a cleaner 48, such as a UV light or incinerator, which kills or destroys a substantial, if not all, the bio-load in the discharge. After the bio-load is substantially removed, the remaining discharge is exhausted to the air through a vent 50. Optionally, the system may include a deodorizer to minimize any odors that may be discharged despite the filtering and destruction of the bio-load.
To further facilitate the delivery of the drug, the drug may be suspended in a carrier, such as a lipid based drug carrier or other liquids, such as solvents or excipients, which will also facilitate drug delivery. Further, the drugs may be applied in concentrated form, for example when directly to the tissue as noted above. In addition, a patient may take a vasodilator, orally for example, which may facilitate the circulation of the patient's capillaries in the vicinity of the application, while a second drug may be applied to the tissue using the through-the-surface-tissue drug delivery system of the present invention. Therefore, it should be understood that the present invention may be used in combination with conventional treatment methods.
As noted above, the present drug delivery system may be used to minimize drug interaction between two or more drugs. For example, one drug may be administered orally, as noted above, or injected (or through a suppository, e.g.), while a second drug may administered using the drug delivery system of the present invention. In addition, as will be more fully described below, specific regions of the patient's body may be targeted for drug treatment. Therefore, the drug system may be used to administer more than one drug, with a third drug administered using the drug delivery system of the present invention that targets a specific region of the patient's body.
The drugs may be stored in a reservoir 120 similar to the previous embodiment and delivered into chamber 112 and, further, into liquid 113 contained in chamber 112. The flow of the drug from reservoir 120 may similarly controlled by a control system; such as described above. In this manner, chamber 112 provides pressurized air over a drug suspended in a liquid. Optionally, as in the case of the previous embodiment, system 110 may include a temperature controller to heat the liquid and a skin poration device, which applies energy to skin of the patient in the form of energy waves, sound waves, voltage or current to enlarge the pores of the patient's skin and thereby facilitate absorption of the drug through the surface tissue. Further, the liquid in chamber 112 may be circulated to facilitate the mixing of the drugs in liquid and, further, in the case of wound treatment provide debridement of the wound. For example, the liquid the liquid 113 may be circulated in chamber 112 by continually flushing the liquid in the chamber, by continuously filling the chamber through inlet 131 and draining the liquid through the drain outlet 140. Alternately, liquid 113 may be circulated by air or gas injected into the fluid through a second inlet port, for example inlet port 131 a, which allows air to be injected into liquid 113 while restricting the flow of liquid 113 out of chamber 112.
The discharge from chamber 112 may also be filtered, precipitated and then cleansed by UV radiation, for example, similar to the previous embodiment. Therefore, for further details regarding the discharge reference is again made to the previous embodiment.
As best seen in
It should be understood that the chamber of the present invention may be configured to treat various appendages of the patient and various areas of the patient. For example, referring to
In the illustrated embodiment, an access port 316 to allow a patient's wrist to be inserted into chamber 312 is provided in the side of the chamber, though it should be understood that the access port may be located on the top wall of the chamber as well. Further, port 316 is provided with a boot or sleeve or pressure cuff to seal chamber 312.
Alternately, as seen in
As best seen in
As noted above the size and shape of the chambers may be varied. Referring to
With reference to system 1210, the total body of a patient may be immersed in chamber 1212 and may optionally form a sensory deprivation chamber with high breathable oxygen content and medication delivered to the patient via the liquid 1213, such as water or perafluorocarbons. Perafluorocarbons carry oxygen so well that a person may in theory be immersed in perafluorocarbon and still breathe.
In the illustrated embodiment, chamber 1312 is configured to comprise a partial body chamber with the child or infant suspended at the insertion port 1316 by, for example (not shown) a harness or the like. Alternately, the sleeve 1316 a that forms the seal between the infant's body and the chamber may be configured as a harness to thereby suspend the child in the chamber 1312. Optionally, chamber 1312 may be placed on a weigh scale system 1350 to determine monitored drug dosage. In this manner, an infant or toddler may be treated with multiple drugs with no painful injection.
For further details of the various optional components and methods of treatment of drug delivery systems 310-2310, reference is made to drug delivery systems 10 and 110. In addition, any one of the chambers described herein may be used in conjunction with a pulsed lavage treatment or debridement treatment. For example, an access port may be provided that allows the tip of a lavage or debridement device to be inserted into the chamber. Thus, when administering a drug to a wound, enhanced treatment may be achieved when combined with cleansing of the wound bed, such as by lavage or debridement. For example of suitable devices for lavage or debridement treatment reference is made hereinto U.S. Pat. Nos. 4,278,078; 5,810,770; 6,471,668; 6,179,807, 6,6652,488; 6,371,934; 6,099,494; and 7,153,287, which are all commonly owned by Stryker Corporation of Kalamazoo, Mich. and which are incorporated by reference in their entireties herein. Further, any one of the chambers described herein may be used to treat dermatological condition, including the translocation of enzymes, antibiotics, drugs and regulatory molecules for the treatment of baldness, cellulite, infections, scar tissue and other skin disorders. Further, the chamber may be used to apply a vacuum to extract or remove, for example, dyes or other fluids from a patient's body.
Accordingly, the present invention provides a drug delivery system that may enhance absorption of a drug containing liquids or creams that are applied directly to the patient's tissue, such as skin, by pressurizing the patient's tissue. Alternately, the drug may be directed to the patient's tissue in a gas, vapor, or liquid form, or combination thereof, which is delivered in a pressurized chamber to thereby enhance the through-the-surface-tissue absorption of the drug by the patient. Consequently, the present invention eliminates the need for injection or suppository use. Further, multiple drugs may be delivered simultaneously or sequentially, which may minimize drug-to-drug interaction associated with oral dosage forms of the drug.
While several forms of the invention have been shown and described, other forms will now be apparent to those skilled in the art. As noted above, the present invention may be used to treat a variety of conditions, including the treatment of wounds, alleviation of pain, treatment of dermatological conditions, including baldness, cellulite, infections, scar tissue and other skin disorders.
For example, features of one embodiment may be combined with features of another embodiment. Therefore, it will be understood that the embodiments shown in the drawings and described above are merely for illustrative purposes, and are not intended to limit the scope of the invention which is defined by the claims which follow as interpreted under the principles of patent law including the doctrine of equivalents.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US753990||Nov 1, 1902||Mar 8, 1904||Julius Luetje||Method of and apparatus for impregnating parts of the body with medicaments.|
|US1775442||Nov 3, 1928||Sep 9, 1930||Sarason David||Apparatus for the hot treatment of parts of the body|
|US2099744 *||Jul 16, 1930||Nov 23, 1937||Fillor Famous Facial Corp||Method of and means for exterior body treatments|
|US2435894||Jun 4, 1946||Feb 10, 1948||Neo Beauty Line Company Ltd||Breast massaging device|
|US2970073 *||Oct 28, 1959||Jan 31, 1961||Howe Sound Co||Method for ultrasonic surgical cleaning of human body members|
|US3195539||Aug 7, 1963||Jul 20, 1965||Hyman Cyril D||Moist heat treatment device|
|US3288140||Oct 4, 1963||Nov 29, 1966||Mccarthy John J||Means for treating surface wounds|
|US3315665||Oct 11, 1963||Apr 25, 1967||Norman A Macleod||Method and apparatus for therapy of skin tissue|
|US3659600 *||Feb 24, 1970||May 2, 1972||Charles River Foundation The||Magnetically operated capsule for administering drugs|
|US3712298||Aug 25, 1970||Jan 23, 1973||Nat Res Dev||Medical treatment apparatus|
|US3785374||Jul 13, 1972||Jan 15, 1974||H Lipson||Sealable container for liquid flotation of cast-bound limbs|
|US3920006||Jan 2, 1974||Nov 18, 1975||Roy Lapidus Inc||Inflatable device for healing of tissue|
|US4003371||Jan 28, 1976||Jan 18, 1977||Fischer Boguslav||Low pressure hyperbaric chamber|
|US4353359||Jul 16, 1979||Oct 12, 1982||Milbauer Nathaniel A||Portable jacket for treatment and protection of injured body members|
|US4376437||Jul 19, 1979||Mar 15, 1983||Sundheim Benson R||Topical environmental device|
|US4382441||Dec 6, 1979||May 10, 1983||Svedman Paul||Device for treating tissues, for example skin|
|US4460370||Dec 16, 1982||Jul 17, 1984||Almedco, Inc.||Trans-dermal medication application cell|
|US4509513||Sep 29, 1982||Apr 9, 1985||Lasley Robert A||Portable and collapsible hyperbaric chamber assembly|
|US4620538||Mar 19, 1985||Nov 4, 1986||The United States Of America As Represented By The Secretary Of The Air Force||Light-weight oxygen delivery hood assembly for hyperbaric chamber|
|US4624656 *||Dec 24, 1984||Nov 25, 1986||Hospitak, Inc.||Hyperbaric gas treatment device|
|US4801291||Nov 18, 1987||Jan 31, 1989||Loori Phillip E||Portable topical hyperbaric apparatus|
|US4863457||Apr 22, 1988||Sep 5, 1989||Lee David A||Drug delivery device|
|US4886489 *||Jun 19, 1987||Dec 12, 1989||Jacobsen Stephen C||Flow-through methods and apparatus for iontophoresis application of medicaments at a controlled pH|
|US4953565||Mar 28, 1989||Sep 4, 1990||Shunro Tachibana||Endermic application kits for external medicines|
|US5029579||Aug 10, 1989||Jul 9, 1991||Ballard Medical Products||Hyperbaric oxygenation apparatus and methods|
|US5060644||Sep 4, 1990||Oct 29, 1991||Ventnor Corporation||Hyperbaric chamber apparatus|
|US5152757||May 22, 1991||Oct 6, 1992||Brigham And Women's Hospital||System for diagnosis and treatment of wounds|
|US5154697||Apr 2, 1991||Oct 13, 1992||Topox, Inc.||Collapsible topical hyperbaric apparatus|
|US5176663||Sep 11, 1991||Jan 5, 1993||Pal Svedman||Dressing having pad with compressibility limiting elements|
|US5228431||Nov 19, 1990||Jul 20, 1993||Giarretto Ralph R||Drug-free method for treatment of the scalp for therapeutic purposes|
|US5312385||Oct 9, 1991||May 17, 1994||University Of Pittsburgh||Device for protected pulse irrigation|
|US5358494||Sep 16, 1993||Oct 25, 1994||Svedman Paul||Irrigation dressing|
|US5447504||May 3, 1993||Sep 5, 1995||Baker; Gregg R.||Misting apparatus for the treatment of injured areas and method therefor|
|US5607408||Dec 9, 1994||Mar 4, 1997||Boucly; Yvonne||Application of active skin treatments under neutral atmosphere|
|US5607418||Aug 22, 1995||Mar 4, 1997||Illinois Institute Of Technology||Implantable drug delivery apparatus|
|US5688236||May 17, 1996||Nov 18, 1997||Stephen's Medical, Inc.||Topical hyperbaric device for treating skin disorders|
|US5738093||Mar 13, 1996||Apr 14, 1998||Gse Giunio Santi Engineering S.R.L.||Flexible hyperbaric chamber|
|US5788682||Apr 28, 1995||Aug 4, 1998||Maget; Henri J.R.||Apparatus and method for controlling oxygen concentration in the vicinity of a wound|
|US5795314||Jun 19, 1996||Aug 18, 1998||Berenstein; Moshe||Therapeutic fingernail treatment device|
|US5810795||May 13, 1996||Sep 22, 1998||Westwood; Joseph R.||Hyperbaric device with secondary pressure zone|
|US5837281 *||Mar 12, 1996||Nov 17, 1998||Takeda Chemical Industries, Ltd.||Stabilized interface for iontophoresis|
|US5848998 *||Jul 11, 1996||Dec 15, 1998||Marasco, Jr.; Patrick V.||Tissue debriding apparatus|
|US5865722||Apr 4, 1997||Feb 2, 1999||Numotech, Incorporated||Shape-adaptable topical hyperbaric oxygen chamber|
|US6013094||Aug 14, 1997||Jan 11, 2000||Otto Bock Orthopaedische Industrie Besitz- Und Verwaltungskommandit- Gesellschaft||Method and device for treating scar tissue|
|US6060020||Apr 9, 1998||May 9, 2000||S.P.M. Recovery Technologies Ltd||Method and apparatus for treating objects with ozone|
|US6251100 *||Oct 22, 1997||Jun 26, 2001||Transmedica International, Inc.||Laser assisted topical anesthetic permeation|
|US6398767||May 27, 1998||Jun 4, 2002||Wilhelm Fleischmann||Process and device for application of active substances to a wound surface area|
|US6416293 *||Jul 20, 1999||Jul 9, 2002||Deka Products Limited Partnership||Pumping cartridge including a bypass valve and method for directing flow in a pumping cartridge|
|US6432077||Dec 26, 2000||Aug 13, 2002||Sensormedics Corporation||Device and method for treatment of surface infections with nitric oxide|
|US6458109 *||Aug 5, 1999||Oct 1, 2002||Hill-Rom Services, Inc.||Wound treatment apparatus|
|US6471685||May 18, 2000||Oct 29, 2002||David James Johnson||Medical dressing assembly and associated method of using the same|
|US6584971||Jun 30, 2000||Jul 1, 2003||Medic-Aid Limited||Drug delivery apparatus|
|US6635035||Jul 21, 2000||Oct 21, 2003||Patrick V. Marasco||Tissue irrigation arrangement|
|US6685681||Nov 29, 2000||Feb 3, 2004||Hill-Rom Services, Inc.||Vacuum therapy and cleansing dressing for wounds|
|US6752794||Nov 27, 2001||Jun 22, 2004||Hill-Rom Services, Inc.||Vacuum therapy and cleansing dressing for wounds|
|US6755807||Nov 29, 2000||Jun 29, 2004||Hill-Rom Services, Inc.||Wound treatment apparatus|
|US6764462||May 31, 2002||Jul 20, 2004||Hill-Rom Services Inc.||Wound treatment apparatus|
|US6800074||Nov 29, 2000||Oct 5, 2004||Hill-Rom Services, Inc.||Wound treatment apparatus|
|US6810288||Mar 12, 2002||Oct 26, 2004||Ceramatec, Inc.||Device and method for wound healing and infection control|
|US6824533||May 31, 2002||Nov 30, 2004||Hill-Rom Services, Inc.||Wound treatment apparatus|
|US6855135||May 13, 2002||Feb 15, 2005||Hill-Rom Services, Inc.||Vacuum therapy and cleansing dressing for wounds|
|US6905459||Apr 9, 2003||Jun 14, 2005||Arthur L. Humphries, Jr.||Device for treating erectile dysfunction|
|US6951215||Jul 14, 2000||Oct 4, 2005||Tufts University||Drug delivery device for animals|
|US7022113||Jul 11, 2002||Apr 4, 2006||Hill-Rom Services, Inc.||Control of vacuum level rate of change|
|US7195624||Dec 20, 2002||Mar 27, 2007||Hill-Rom Services, Inc.||Vented vacuum bandage with irrigation for wound healing and method|
|US7216651 *||May 23, 2001||May 15, 2007||Wake Forest University Health Sciences||Wound treatment employing reduced pressure|
|US20020017299 *||Jul 23, 2001||Feb 14, 2002||Hickle Randall S.||Apparatus and method for providing a conscious patient relief from pain and anxiety associated with medical or surgical procedures|
|US20020160057||Jul 7, 2001||Oct 31, 2002||Park Joseph Min H.||Device for eliminating poisons from the human body and for revitalizing cells|
|US20050261615||May 19, 2005||Nov 24, 2005||Richard Scott Weston||Hypobaric chamber treatment system|
|US20060185670||Feb 24, 2005||Aug 24, 2006||Phillip Loori||Hyperbaric oxygen devices and delivery methods|
|US20070041960||Jul 25, 2006||Feb 22, 2007||Ramot At Tel-Aviv University Ltd., Enzysurge Ltd.||Apparatus and methods for enzymatic debridement of skin lesions|
|US20070299369 *||Jun 26, 2006||Dec 27, 2007||Eilaz Babaev||Ultrasound wound care device and method|
|US20080005840 *||Jul 6, 2006||Jan 10, 2008||General Electric Company||Apparatus for supporting a patient in a prone position during diagnostic imaging|
|1||P. Svedman et al., "Staphylococcal Wound Infection in the Pig: Part I. Course," Ann. Plast. Surg. 23(3):212-218, (Sep. 1989). NPL-684.|
|2||P. Svedman et al., A Dressing Allowing Continuous Treatment of a Biosurface, IRCS Medical Science: Biomedical Technology; Clinical Medicine; Surgery and Transplantation, vol. 7, Mar. 1979, p. 221.|
|3||P. Svedman et al., A Dressing System Providing Fluid Supply and Suction Drainage Used for Continuous or Intermittent Irrigation, Annals of Plastic Surgery, vol. 17, No. 2, Aug. 1986, pp. 125-133.|
|4||P. Svedman, Irrigation Treatment of Leg Ulcers Lancet, 1:532, 1983.|
|5||PCT International Search Report mailed Jan. 21, 2009, for corresponding PCT Application No. PCT/US2008/073090.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8241258 *||Jul 24, 2006||Aug 14, 2012||Iyia Technologies, Inc.||Wound treatment system and method of use|
|US8353882||Feb 8, 2010||Jan 15, 2013||Iyia Technologies, Inc.||Wound treatment system and method of use|
|US8663179||Dec 10, 2012||Mar 4, 2014||Cure Care, Inc.||Wound treatment system and method of use|
|US8758310 *||Aug 26, 2011||Jun 24, 2014||Mark R. Moore||Apparatus and method for deploying a surgical preparation|
|US20100022941 *||Jul 24, 2006||Jan 28, 2010||Adrian Pelkus||Wound treatment system and method of use|
|US20110178456 *||Apr 2, 2010||Jul 21, 2011||The Regents Of The University Of California||Assisting transdermal drug delivery by means of tissue freezing, vacuum pressure and photoheating procedures|
|US20120053536 *||Aug 26, 2011||Mar 1, 2012||Moore Mark R||Apparatus and method for deploying a surgical preparation|
|U.S. Classification||604/290, 604/289, 604/500, 604/293, 604/305, 601/17|
|International Classification||A61M35/00, A61H1/00, A61F13/00, A61M31/00|
|Cooperative Classification||A61H33/14, A61M35/00, A61H35/006, A61H2201/105, A61H9/005|
|European Classification||A61M35/00, A61H35/00F, A61H33/14, A61H9/00P|
|Aug 21, 2008||AS||Assignment|
Owner name: STRYKER CORPORATION, MICHIGAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STRYKER, MARTIN W.;ENGELMAN, DONALD M., DR.;REEL/FRAME:021420/0758;SIGNING DATES FROM 20080807 TO 20080811
Owner name: STRYKER CORPORATION, MICHIGAN
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STRYKER, MARTIN W.;ENGELMAN, DONALD M., DR.;SIGNING DATES FROM 20080807 TO 20080811;REEL/FRAME:021420/0758
|Apr 15, 2015||FPAY||Fee payment|
Year of fee payment: 4